ARTICLE | Clinical News
Mirabegron regulatory update
August 9, 2010 7:00 AM UTC
Astellas disclosed in its quarterly financial results that it submitted an NDA in Japan for mirabegron to treat urinary frequency, urinary incontinence or urgency associated with overactive bladder. T...